This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

InOncology.com

CSCO 2018

Chinese Society of Clinical Oncology 2018

At the CSCO 2018 annual meeting, Boehringer Ingelheim presented a number of publications, highlighting our advances in the treatment of lung cancer.

5 Publications
4 Downloads
19th–23rd September 2018
Xiamen International Conference Center, Xiamen, China
Publications

Please see downloadable versions below.

Filter by:
Presentation Type
  • Oral Presentation
  • Poster Presentation
  • e-Presentation
Tumour Type
Thursday 20th September 2018
Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive (EGFRm+) non-small-cell lung cancer
Author(s): Wu et al.
Oral Presentation
Tumour Type(s): NSCLC
Presentation Number: TBC
Afatinib* in chemotherapy pre-treated EGFR mutation-positive NSCLC
Author(s): Thongprasert et al.
Oral Presentation
Tumour Type(s): NSCLC
Presentation Number: TBC
Afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC harboring uncommon mutations: overview of clinical data
Author(s): Wu et al.
Oral Presentation
Tumour Type(s): NSCLC
Presentation Number: TBC
Competing central nervous system or systemic progression analysis for patients with EGFR mutation-positive NSCLC receiving afatinib in LUX-Lung 3, 6, and 7
Author(s): Wu et al.
Poster Presentation
Tumour Type(s): NSCLC
Presentation Number: P5
Afatinib (afa) in lung squamous cell carcinoma (SCC): a clinical overview, with a focus on Chinese patients (pts), and potential combination with pembrolizumab (pemb)
Author(s): Lu et al.
e-Presentation
Tumour Type(s): NSCLC
Abstract Number: TBC
There are no publications which meet your criteria on this date

Find out more about other oncology events

Click here to find out more about other oncology meetings, congresses,
symposia and activities sponsored by Boehringer Ingelheim.

*Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.

 

© 2018 Boehringer Ingelheim International GmbH. All rights reserved.

Last updated: September 2018